<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-128930</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Ventricular arrhythmias in super-responders to cardiac resynchronization therapy</dc:title>
<dc:description xml:lang="en">Introduction and objectives: Cardiac resynchronization therapy is associated with improved quality of life and reduced morbidity and mortality in patients with severe ventricular dysfunction and wide QRS. However, its role in the reduction of ventricular arrhythmias is more controversial. Methods: We compared the incidence of ventricular arrhythmias in patients who were undergoing cardiac resynchronization therapy with an implantable cardioverter-defibrillator in terms of the degree of echocardiographic response to resynchronization. Patients were classified in 3 subgroups; superresponders, responders, and non responders. Results: We included 196 patients who were followed up for a median 30.1 months [interquartile range,18.0-55.1 months]. We recorded the presence of ventricular arrhythmias in 37 patients (18.8%);3 patients (5.9%) in the super-responder group had ventricular arrhythmias vs 14 (22.2%) among the responders and 20 (24.4%) in the group of non responders (P = .025). In multivariate analysis, the only independent predictors of the appearance of ventricular arrhythmias were secondary&#150;prevention (..) (AU)</dc:description>
<dc:creator>Mingo-Santos, Susana</dc:creator>
<dc:creator>Pérez-Pereira, Elena</dc:creator>
<dc:creator>Delgado, Hugo E</dc:creator>
<dc:creator>Moñivas-Palomero, Vanessa</dc:creator>
<dc:creator>Sánchez-García, Manuel</dc:creator>
<dc:creator>Fernández-Lozano, Ignacio</dc:creator>
<dc:creator>García-Lunar, Inés</dc:creator>
<dc:creator>Toquero-Ramos, Jorge</dc:creator>
<dc:creator>Daniela Mitroi, Cristina</dc:creator>
<dc:creator>Castro-Urda, Víctor</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción y objetivos La terapia de resincronización cardiaca se asocia a mejora de la calidad de vida y reducción de la morbimortalidad de los pacientes con disfunción ventricular grave y QRS ancho. Sobre su papel en la reducción de arritmias ventriculares, hay más discusión. Métodos Se comparó la incidencia de arritmias ventriculares en pacientes portadores de desfibrilador automático implantable con función de resincronización cardiaca, según el grado de respuesta ecocardiográfica a la resincronización. Se clasificó a los pacientes en tres subgrupos: superrespondedores, respondedores y no respondedores. Resultados Se incluyó a 196 pacientes seguidos durante una mediana de 30,1 [intervalo intercuartílico, 18,0-55,1] meses. Se documentó presencia de arritmias ventriculares en 37 pacientes (18,8%); 3 pacientes (5,9%) del grupo de superrespondedores presentaron arritmias ventriculares, en comparación con 14  (..) (AU)</dc:description>
<dc:source>Rev Esp Cardiol;67(11): 883-889, nov. 2014. ilus, tab</dc:source>
<dc:identifier>ibc-128930</dc:identifier>
<dc:title xml:lang="es">Arritmias ventriculares en superrespondedores a la terapia de resincronización cardiaca</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d54223^s22074</dc:subject>
<dc:subject>^d21027^s22074</dc:subject>
<dc:subject>^d28625</dc:subject>
<dc:subject>^d15100^s22067</dc:subject>
<dc:subject>^d10326^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:type>article</dc:type>
<dc:date>201411</dc:date>
</metadata>
</record>
</ibecs-document>
